Forty-five patients with metastatic breast cancer without clinically evident disease were treated with thiotepa 750 mg/m 2 , mitoxantrone 40 mg/m 2 and carboplatin 1000 mg/m 2 followed by stem cell transplantation to determine the safety and efficacy of CD34 + selection of peripheral blood stem cells. Of these, 15 patients' (group I) stem cells were processed through Baxter Isolex 300 device for CD34 + selection, whereas 30 patients (group II) received unmanipulated stem cells. Toxicity, progression-free survival and survival were compared between these two groups. There was no difference in transfusion requirements, white cell count and platelet recovery and non-hematologic toxicity between the two groups. The survival of patients in group I was 27 months compared to 38 months in group II (P = 0.8). The progression-free survival was 12 months and 13.5 months for group I and group II patients, respectively (P = 0.6). Our results indicate that while there is no adverse effect, there is also no significant advantage of CD34 + selection in terms of progression-free survival and survival in patients with metastatic breast cancer without clinically evident disease. Bone Marrow Transplantation (2000) 25, 1041-1045. Keywords: CD34 + selection; PBSC transplantation; metastatic breast cancer High-dose chemotherapy (HDC) with peripheral blood stem cell (PBSC) transplantation has been shown to be effective in patients with metastatic carcinoma of the breast. [1] [2] [3] [4] In patients who achieve a complete remission with chemotherapy, long-term disease-free survival can be obtained by a variety of different HDC regimens. 1, 2, 5, 6 The use of high-dose chemotherapy with stem cell rescue has allowed dose-intensity to be maximized and morbidity and mortality to be reduced. In fact, in most series, peri-transplant mortality now is below 5%. 4, 7 This has allowed wide- [12] [13] [14] In order to reduce the risk of relapse due to tumor cells in the PBSC preparation, a variety of techniques has been applied. Negative selection techniques using chemotherapeutic agents or monoclonal antibodies have been shown to deplete tumor cells by 3 logs. 15, 16 Selection techniques that enrich the preparation with CD34 + cells and deplete tumor cells in the PBSC preparation have also been used. [17] [18] [19] We investigated the use of CD34 + selection in patients with metastatic breast cancer undergoing HDC with PBSC, and compared the results to those noted in other patients with metastatic breast cancer undergoing identical conditioning and post-transplant care whose stem cell product was not CD34 + selected.
spread use of this therapy for patients with metastatic breast cancer. Recurrence of disease following dose-intensive therapy remains a major problem.
Various studies have demonstrated that in cases of acute leukemia, 8 neuroblastoma, 9 and lymphoma 10 relapse of disease is, at least in part, related to infusion of tumor cells present in the stem cell inoculums. In cases of breast cancer, cytokeratin-positive cells, 11 which presumably represent tumor cells, have been demonstrated in peripheral blood stem cell preparations. Whether these are actual tumor cells, and if they are tumor cells, whether they are clonogenic and possess metastatic potential has not been proven. [12] [13] [14] In order to reduce the risk of relapse due to tumor cells in the PBSC preparation, a variety of techniques has been applied. Negative selection techniques using chemotherapeutic agents or monoclonal antibodies have been shown to deplete tumor cells by 3 logs. 15, 16 Selection techniques that enrich the preparation with CD34
+ cells and deplete tumor cells in the PBSC preparation have also been used. [17] [18] [19] We investigated the use of CD34 + selection in patients with metastatic breast cancer undergoing HDC with PBSC, and compared the results to those noted in other patients with metastatic breast cancer undergoing identical conditioning and post-transplant care whose stem cell product was not CD34 + selected.
Materials and methods

Patient selection
Forty-five consecutive patients with metastatic breast cancer that had been rendered free of clinically evident disease by using chemotherapy only or in combination with surgery, radiation or hormonal manipulations were eligible for PBSC transplantation following dose-intensive therapy.
Patients were required to have histological documentation of breast cancer, age over 18 years, performance status р2 on the ECOG scale, white count у3 × 10 у40% of predicted). Patients were excluded if they were infected with HIV1 and 2, or had detectable hepatitis B surface antigen. Patients with brain metastasis were excluded. All patients were required to give written informed consent approved by the Institutional Review Board of New York Medical College. + selection, a backup of 2.0 × 10 6 CD34 + unselected cells/kg were collected. PBSCs were processed using the Baxter Isolex 300 device (Baxter, Deerfield, IL, USA) using a previously described technique. 19 Peripheral blood stem cells or CD34 + cells were then cryopreserved using the method described by Stiff and co-workers 20 and was stored in mechanical freezers or liquid nitrogen vapor. Preand post-CD34 + selection samples were analyzed for residual tumor by immunocytochemical techniques as previously described. ). At least 2.0 × 10 6 CD34 + cells/kg patient body weight were infused on the seventh day from the start of chemotherapy (considered day 0 of stem cell transplantation). GM-CSF 500 g was given daily until neutrophil count reached Ͼ1 × 10 9 /l. Post transplant patients were cared for in hospital rooms equipped with HEPA-filtered air handling systems. Prophylactic fluconazole, acyclovir, cotrimoxazole and anti-emetics were given. Total parenteral nutrition, intravenous narcotics for relief of mucosal pain, antibiotics, anti-fungal and anti-viral medications, cytokines, and blood transfusions were given as necessary. Initially, attempts were made to keep the hemoglobin over 10 g/dl and platelet counts above 20 × 10 9 /l. Subsequent changes in policy at our institutions vis-à-vis supportive care techniques led to the triggers for transfusion to be reduced to 8 g/dl of hemoglobin and 10 × 10 9 /l of platelets. Following high-dose chemotherapy, no additional chemotherapy was offered.
Stem cell mobilization and processing
The two groups, ie CD34 + selected (group I) and unselected (group II) were compared in terms of survival, progression-free survival and toxicity. Survival was calculated from the time of transplant to the time of death. Progression-free survival was calculated from the day of transplant to the day of progression of disease.
Statistical methods
Actuarial survival and progression-free survival curves were constructed according to Kaplan-Meier estimates using SAS/STAT software (Cary, NC, USA). The Wilcoxon test was used to determine the statistical differences in survival and progression-free survival between CD34 + selected and unselected patients.
Results
Patient characteristics
Forty-five patients were treated with thiotepa, mitoxantrone, and etoposide (TMJ) as the conditioning regimen followed by PBSC transplant. The median age was 46 years (range 26-64), with a median ECOG performance score of 0 (range 0-1). Twenty-nine patients were pre-menopausal, 21 tested positive for estrogen receptors and/or progesterone receptors. Hormone receptor status was not available for three patients. Twenty-two patients had prior irradiation, and 19 had prior hormonal therapy. Four patients had metastatic disease at diagnosis and nine had two or more relapses. Thirty-six patients had one area of metastatic disease: 16 had lymph nodes other than ipsilateral axillary nodes, 12 had skin/soft tissue disease, four had bone, two had liver and two had lung metastasis. Of nine patients with more than one site of disease, visceral metastases were present in four. The median number of prior chemotherapeutic regimens was two (range 1-4). Forty-one patients had prior anthracyclines, and 30 had prior taxanes. Twenty-four patients achieved disease-free status with chemotherapy alone, whereas 14 also required surgical resection, six had irradiation, and two had prior hormones as well.
Depending on whether or not a given patient's stem cells were CD34 + selected or not, patients were divided into two groups. Group I consisted of 15 patients who had CD34 + selected cells, while group II consisted of 30 patients who did not. The comparison of these groups is shown in Table  1 . There was no significant difference in characteristics of the patients in these two groups.
Toxicity
Hematologic toxicity for all patients and individual groups are summarized in Table 2 . Mucositis was the major nonhematologic toxicity. Ten (67%) patients in group I (CD34 selected) and 20 (67%) patients in group II developed grade 3-4 mucositis. Five (33%) patients in group I and eight (27%) patients in group II had grade 3-4 infection. Two patients in each group developed grade 3-4 diarrhea. Two patients in group II developed mild renal insufficiency that did not require dialysis. Six patients in group II and one patient in group I developed hyperbilirubinemia. Two patients died within the first 60 days. One patient in group I died of multi-organ failure. One patient in group II died prior to stem cell infusion, possibly secondary to pulmonary embolism.
Micro-metastases
Five of the patients in group I had detectable levels of breast micro-metastases in their PBSC collection as measured by immunocytochemistry. For all five patients the micrometastases detected prior to CD34 + selection were undetectable in the transplanted CD34 + selected product.
Survival
Survival and progression-free survival of all 45 patients were 38.3 months and 13.5 months, respectively. Median
Bone Marrow Transplantation follow-up was 29 months. The median survival was 26.9 months for group I and 38.3 months for group II (P = 0.8; Figure 1 ). The progression-free survival was 12.1 months for group I and 13.5 months for group II (P = 0.6; Figure  2 ). Major sites of relapse included local relapse in sites of previous disease exclusively in seven patients in group I and 18 patients in group II. Relapse in additional sites occurred in three patients in group I and 11 patients in group II. Three patients in each group had relapsed in both old and new sites of disease.
Discussion
Dose-intensive chemotherapy has emerged as a frequently used strategy for treating patients with advanced metastatic breast cancer (Table 3 ). The regimen of BCNU, cisplatin and cyclophosphamide was associated with significant pulmonary toxicity and high peri-transplant mortality. 29 Other regimens did not circumvent the problem entirely. The regi-
CD34
+ selected PBSC transplant for breast cancer T Ahmed et al men of thiotepa, mitoxantrone and carboplatin has been tolerated well in our experience and has a low incidence of extra-medullary toxicity.
Various purging techniques reduced tumor cell contamination by a factor of 3-4 logs. 15, 16 CD34 + selection provides a stem cell preparation enriched with progenitor cells. [17] [18] [19] It has been stated that cytokeratin positivity purportedly identifies tumor cells in the stem cell product, however whether these cells have metastatic potential has not been conclusively demonstrated and their clinical relevance is not clear. [12] [13] [14] In the current study, the addition of CD34 + selection did not effect hematological recovery. There was no increase in either hematologic or non-hematologic side-effects.
Selection of patients who had responsive disease leads to an improvement in results. 1, 5 Patients who were in complete remission prior to transplant had superior outcome. 5 Our results were obtained in consecutive patients achieving complete remission with chemotherapy alone or chemotherapy with surgery or radiation. Previous HDC and PBSC transplantation was not permitted. The time to relapse was not altered by CD34 + selection. The data presented here and elsewhere 5 show that relapse occurs predominantly in sites of original disease. The most frequent site of relapse in our experience in both the groups was in areas of previous involvement. However, there were patients in both groups who experienced relapse exclusively in new sites. This indicates that CD34
+ selection did not provide absolute protection against the systemic relapse. It is possible that there may be differences between the two groups, but the sample size here did not permit evaluation of the potential advantage of this technique.
Prospective randomized trials with responsive metastatic breast cancer have not conclusively demonstrated the advantage of dose-intensive therapy. In the recently presented randomized trial, there was inadequate sample size to conclusively demonstrate the efficacy of dose-intensive therapy in these patients. 30 A large review of the North American experience showed that the subgroup of patients in complete remission achieved prolonged disease-free survival. 1 In conclusion, the regimen of thiotepa, carboplatin and mitoxantrone is tolerated well by patients with metastatic breast cancer who are in complete remission. CD34
+ cell selection does not adversely influence outcome but does not appear to protect from relapse in new or old sites of disease.
